What's happening in the global effort to understand and cure HIKESHI-related leukodystrophy.
This page tracks peer-reviewed research and public scientific reports related to HIKESHI-related hypomyelinating leukodystrophy (HHL). We summarize and link to original publications. We are not affiliated with the researchers or institutions cited; this is independent reporting on the field.
A decade of HIKESHI research.
Each year, the picture gets clearer. Each discovery brings us closer to a treatment.
2015
HIKESHI's role in heat-stress protection is established
2016
Disease-causing V54L mutation discovered in Ashkenazi Jewish families
2016
Second mutation (C4S) found in Finnish patient
2021
Largest clinical study; carrier frequency confirmed at ~1 in 216
2021
HIKESHI protein structure mapped
2023
Mechanism of myelin damage shown at the cellular level
2025
First human iPSC models created; new P78S variant identified
2025
GLIA scientific meeting convenes global leukodystrophy community
Published research, in plain language.
Peer-reviewed studies on HIKESHI-related leukodystrophy, newest first. Each card links to the original publication.
September 24–26, 2025Conference
Leukodystrophy Research Community Convenes at Children's Hospital of Philadelphia
The Global Leukodystrophy Initiative (GLIA) hosted its 2025 Scientific Meeting and Advocacy Workshop in Philadelphia. The three-day event brought together clinical, scientific, advocacy, and industry stakeholders from around the world to review recent advances across the leukodystrophies. Sessions covered newborn screening, therapeutic development, and patient advocacy — all relevant to the broader effort to bring treatments to children with rare myelin disorders, including HHL. Video recordings and presentation materials from the meeting are publicly available.
The Global Leukodystrophy Initiative (GLIA), Children's Hospital of Philadelphia
Researchers Create First Human Cell Models of HHL and Identify a New Disease-Causing Mutation
A study published in the International Journal of Molecular Sciences reports the generation of induced pluripotent stem cells (iPSCs) from patients with HHL — the first comprehensive human cellular model of the disease. The same study identifies a novel pathogenic variant (P78S) in a patient of Christian Arab origin, expanding the known genetic spectrum of HHL beyond the previously documented Ashkenazi Jewish and Finnish populations. The cell models reproduce key disease features, including impaired heat-shock response and disrupted nuclear translocation of HSP70. Importantly, this is the kind of research platform that can accelerate the testing of potential gene therapies.
Authors: Saleh MA, Boichuck M, Ottolenghi A, Rabinski T, Goldenthal O, Sanchez DS, Fattal-Valevski A, Heimer G, Ben-Shachar S, Libzon S, Gershoni-Yahalom O, Ben-Zvi A, Zarivach R, Zerem A, Rosental B, Vatine GD.
International Journal of Molecular Sciences, Vol. 26, Issue 13, Article 6037. DOI: 10.3390/ijms26136037
Comprehensive Review: Thermal Stress and Nuclear Transport in Health and Disease
A scientific review published in Advances in Experimental Medicine and Biology examined the mechanisms by which cells respond to heat stress, including the role of nuclear transport proteins such as HIKESHI. The review consolidates current understanding of how HIKESHI shuttles the heat-shock protein HSP70 into the cell nucleus during fever and stress conditions — a process disrupted in HHL patients. This kind of foundational science is essential context for any future therapeutic development.
Authors: Kose S, Ogawa Y, Imamoto N.
Advances in Experimental Medicine and Biology, 2024;1461:61–78. DOI: 10.1007/978-981-97-4584-5_5. PMID: 39289274
Nature Journal Reviews How Nuclear Transport Proteins Connect to Human Disease
A comprehensive review published in Signal Transduction and Targeted Therapy examined the structure, function, and disease relevance of nuclear transport proteins — the molecular machinery that moves essential proteins in and out of the cell nucleus. HIKESHI is one such transporter, and its disruption in HHL is part of a broader picture: defects in nuclear transport are increasingly recognized as drivers of disease. This kind of review helps place HHL in the context of related disorders, opening the door to shared therapeutic strategies.
Authors: Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q.
Signal Transduction and Targeted Therapy, Vol. 8, Article 425, 2023
Study Reveals How HIKESHI Mutations Disrupt Myelin-Producing Cells
Research published as part of the Molecular Genetics and Metabolism series demonstrated that HIKESHI mutations directly impair the differentiation of oligodendrocytes — the brain cells responsible for producing myelin. Using rat primary oligodendrocyte precursor cells, scientists showed that both the V54L (Ashkenazi) and C4S (Finnish) variants inhibit the cells' ability to mature properly. This is the most direct demonstration to date of why HHL causes hypomyelination at the cellular level, providing a reproducible system for testing potential therapies.
Molecular Genetics and Metabolism Reports, 2023 (open access)
Largest Clinical Study to Date: Carrier Frequency in Ashkenazi Jewish Population is 1 in 216
A study published in Pediatric Neurology provided the most detailed clinical characterization of HHL to date. Researchers analyzed seven additional affected individuals and reported a carrier frequency of approximately 1 in 216 in the Ashkenazi Jewish population — based on genotyping data from more than 125,000 individuals. Five of nine documented patients suffered severe morbidity or death during febrile illness. The study also provided neuropathological evidence confirming HHL as a primary myelin disorder, with brain imaging showing diffuse hypomyelination and a thin corpus callosum.
Authors: Stutterd CA, Vanderver A, Hacker JL, Schmidt JL, Helman G, Zerem A, Fattal-Valevski A, Pizzino A, Sase S, LeFevre AN, Ekstein J, Hirsch Y, Almad A, Grinspan JB, Johansson M, Woidill S, Taft RJ, Simons C, Viaene AN, Harding B.
Pediatric Neurology, August 2021. PMID: 34111619. PMC8327280.
Scientists Map the Structure of the HIKESHI Protein
Published structural and functional analysis revealed how the HIKESHI protein recognizes and transports HSP70 — a key heat-shock protein — into the cell nucleus. Understanding the precise 3D structure of HIKESHI is essential for designing therapies that can either correct or replace the defective protein in HHL patients. This structural knowledge underpins all future drug-discovery work targeting this pathway.
Second HIKESHI Mutation Discovered in Finnish Patient — Disease Affects More Populations Than Just Ashkenazi Jews
A study published in the European Journal of Human Genetics identified a different HIKESHI mutation — c.11G>C (C4S) — in a Finnish patient with hypomyelinating leukoencephalopathy. The patient had similar clinical features to Ashkenazi Jewish patients: spasticity, optic atrophy, nystagmus, and severe developmental delay. Structural modeling showed that the mutation destabilizes the HIKESHI protein. This was the first proof that HHL is not exclusive to the Ashkenazi Jewish population — though that remains by far the most affected group.
Authors: Vasilescu C, Isohanni P, Palomäki M, Pihko H, Suomalainen A, Carroll CJ.
European Journal of Human Genetics, 2017 Feb;25(3):366–370. DOI: 10.1038/ejhg.2016.189. PMID: 28000699
Discovery: HIKESHI Mutation Identified as Cause of Ashkenazi Jewish Leukoencephalopathy
A landmark study published in the Journal of Medical Genetics identified the founder mutation Val54Leu (V54L) in the HIKESHI gene as the cause of a previously unexplained leukoencephalopathy associated with early death in Ashkenazi Jewish children. The researchers studied six patients from three unrelated Ashkenazi Jewish families and traced the disease to a single ancestral mutation. This discovery established the genetic basis for what is now known as HIKESHI-related hypomyelinating leukodystrophy (HLD13; OMIM #616881) and opened the door to all subsequent research.
Authors: Edvardson S, Kose S, Jalas C, Fattal-Valevski A, Watanabe A, Ogawa Y, Mamada H, Fedick AM, Ben-Shachar S, Treff NR, Shaag A, Bale S, Gartner J, Imamoto N, Elpeleg O.
Journal of Medical Genetics, Vol. 53, pp. 132–137, 2016
Scientists Discover HIKESHI's Critical Role in Cell Survival During Heat Stress
Published research established that the HIKESHI protein is a specialized nuclear transport receptor required for cell survival after heat stress. The Japanese research team showed that HIKESHI ferries the heat-shock protein HSP70 into the cell nucleus during fever — a process essential for protecting cells from heat-induced damage. This foundational discovery (HIKESHI means 'firefighter' in Japanese, named for its protective function) laid the groundwork for understanding why HHL patients are so vulnerable to fevers.